Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $41.00 price target on Heron Therapeutics (NASDAQ: HRTX) following the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE